Yıl: 2021 Cilt: 9 Sayı: 1 Sayfa Aralığı: 67 - 71 Metin Dili: Türkçe DOI: 10.4274/nkmj.galenos.2021.816166 İndeks Tarihi: 10-05-2021

Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi

Öz:
Amaç: Özefagus kanseri, hastaların çoğunun ileri evrede teşhis edildiği ölümcül bir hastalıktır. Bu çalışmada özefagus kanseri nedeniyle ameliyat edilen hastaların demografik ve klinikopatolojik özelliklerini sunmayı amaçladık.Gereç ve Yöntem: 1985-2018 yılları arasında özefagus patolojisi nedeniyle cerrahi, kemoradyoterapi veya palyatif prosedürler uygulanan toplam 847 hasta retrospektif olarak incelendi. Hastaların yaş, cinsiyet, tümör yerleşimi, histopatolojisi, cerrahi teknik ve kemoradyoterapi öyküleri incelendi.Bulgular: Çalışmada 488 hasta erkek (%60,5) ve 319 hasta kadındı (%39,5). Katılımcıların yaş ortalaması 58,6 olup, %80,1’i 50 yaşın üzerindeydi. Erkeklerin ve kadınların oranı sırasıyla %60,5 ve %39,5 idi. Elde edilen en yaygın patoloji materyali skuamöz hücreli karsinom (%67,5), ardından adenokarsinomdu (%27,7). Toplam özefajektomi 435 hastaya yapıldı ve 38 hastaya distal özefajektomi yapıldı. Transhiatal özefajektomi (n=271, %62,2) en sık yapılan işlemdi.Sonuç: Özefajektomi, özefagus kanserleri için birincil tedavi yöntemidir. Optimal tedaviyi belirlerken uygun hasta seçimi, evreleme ve risk değerlendirmesi yapılmalıdır. Hastaya özel tedavi multidisipliner bir yaklaşımla planlanmalıdır.
Anahtar Kelime:

The 33-year Retrospective Analysis of Esophageal Carcinomas: Cerrahpaşa Experience

Öz:
Aim: Esophageal cancer is a fatal disease where the majority of patients are diagnosed at an advanced stage. In this study, we aimed to present the demographic and clinicopathological characteristics of patients who were operated for esophageal cancer. Materials and Methods: A total of 847 patients who underwent surgery, chemoradiotherapy, or palliative procedures for esophageal pathology between the years of 1985 and 2018 were retrospectively analyzed. Age, gender, tumor location, histopathology, surgical technique, and chemoradiotherapy history of patients were analyzed. Results: In the study, 488 patients were male (60.5%) and 319 were female (39.5%). The ratio of males and females was 1.52. The average age was 58.6 years, and 80.1% were older than 50 years. The most common pathological material obtained was squamous cell carcinoma (67.5%), followed by adenocarcinoma (27.7%). Total esophagectomy was performed in 435 patients; distal esophagectomy was performed in 38 patients. Transhiatal esophagectomy (n=271, 62.2%) was the most common procedure that was performed. Conclusion: Esophagectomy is the primary treatment modality for esophageal cancers. When determining the optimal treatment, appropriate patient selection, staging, and risk assessment should be made. Patient-specific treatment should be planned with a multidisciplinary approach.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
  • 2. Okten I. “Özofagus Kanserleri.” Ankara: İstanbul Tıp Kitabevi; 2003.p.1247-308.
  • 3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-50.
  • 4. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009;101:855-9.
  • 5. Rice TW, Kelsen D, Blackstone EH, Ishwaran H, Patil DT, Bass AJ, et al. Esophagus and Esophagogastric junction. AJCC Cancer staging Manual. 2017;185-202.
  • 6. Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2008;85:751-6.
  • 7. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400-12.
  • 8. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003;105:98-100.
  • 9. Jobe BA, Landreneau RJ, Habib F. “The Management of Esophageal Cancer.” Cameron JL, Cameron. AM, editors. Current Surgical Therapy. 12th edition. Elsevier; 2017. p. 53-62. Available from: https://www.elsevier.com/books/ current-surgical-therapy/cameron/978-0-323-46117-7
  • 10. Fujita H. Anesthesia of Torek’s operation: the first successful resection of a cancer in the thoracic esophagus-an abridged translation of an essay in Japanese. Gen Thorac Cardiovasc Surg. 2017;65:80-4. Epub 2016 Dec 29.
  • 11. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/csr/1975_2008/
  • 12. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19:5598-606.
  • 13. Schlansky B, Dimarino Jr AJ, Loren D, Infantolıno A, Kowalskı T, Cohen S. “A Survey of Oesophageal Cancer: Pathology, Stage and Clinical Presentation.” Aliment Pharmacol Ther. 2006;23:587-93.
  • 14. Asombang AW, Chishinga N, Nkhoma A, Chipaila J, Nsokolo B, Manda- Mapalo M, et al. Systematic review and meta-analysis of esophageal cancer in Africa: Epidemiology, risk factors, management and outcomes. World J Gastroenterol. 2019;25:4512-33.
  • 15. Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;3:289-97.
  • 16. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52.
  • 17. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19:1468-70.
  • 18. Espat NJ, Jacobsen G, Horgan S, Donahue P. Minimally invasive treatment of esophageal cancer: laparoscopic staging to robotic esophagectomy. Cancer J. 2005;11:10-7.
  • 19. Ishihara R, Tanaka H, Iishi H, Takeuchi Y, Higashino K, Uedo N, et al. Long-term outcome of esophageal mucosal squamous cell carcinoma without lymphovascular involvement after endoscopic resection. Cancer. 2008;112:2166-72.
  • 20. Ajani JA, D’amico TA, Bentrm DJ, Chao J, Corvera C, Das P, et al. “Esophageal and Esophagogastric Junction Canser” Version 2.2019. NCCN Clinical Practice Guidelines in Oncology. 2019;17:855-83.
  • 21. Ozcelik MF. Özofagus Kanseri: Tanı ve Cerrahi Tedavi. Gastrointestinal Sistem Hastalıkları. İstanbul, İ.Ü. Cerrahpaşa Tıp Fakültesi; 2001. p. 241-51.
  • 22. Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1993;106:850-8.
  • 23. Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg. 2001;72:306-13.
  • 24. Levy RM, Pennathur A, Luketich JD. Randomized trial comparing minimally invasive esophagectomy and open esophagectomy: early perioperative outcomes appear improved with a minimally invasive approach. Semin Thorac Cardiovasc Surg. 2012;24:153-4.
  • 25. Luketich JD, Pennathur A, Awais O, Levy RM, Keeley S, Shende M, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg. 2012;256:95-103.
  • 26. Takeuchi H, Miyata H, Ozawa S, Udagawa H, Osugi H, Matsubara H, et al. Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan. Ann Surg Oncol. 2017;24:1821-7.
  • 27. Yibulayin W, Abulizi S, Lv H, Sun W. Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a metaanalysis. World J Surg Oncol. 2016;14:304.
  • 28. van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens LAA, Joore HCA, et al. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. Ann Surg. 2019;269:621-30.
  • 29. Ozkaya M, Ozdogan M, Ozyazici S, Das K, Onel S. Minimally Invasive Approach for Mid-Esophageal and A Giant Epiphrenic Diverticula: Case Report. JCAM. 2016;7:268-70.
  • 30. Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol. 2007;4:282-94.
  • 31. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-7.
  • 32. Bozzetti F. Nutritional support in patients with oesophageal cancer. Support Care Cancer. 2010;18:41-50.
APA Uludağ S, AKINCI O, ergun s, Erginöz E, SANLI A, kepil n, Ayan F, OZCELIK M, zengin a (2021). Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. , 67 - 71. 10.4274/nkmj.galenos.2021.816166
Chicago Uludağ Server Sezgin,AKINCI OZAN,ergun sefa,Erginöz Ergin,SANLI AHMET NECATI,kepil nuray,Ayan Fadıl,OZCELIK MEHMET FAIK,zengin abdullah kağan Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. (2021): 67 - 71. 10.4274/nkmj.galenos.2021.816166
MLA Uludağ Server Sezgin,AKINCI OZAN,ergun sefa,Erginöz Ergin,SANLI AHMET NECATI,kepil nuray,Ayan Fadıl,OZCELIK MEHMET FAIK,zengin abdullah kağan Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. , 2021, ss.67 - 71. 10.4274/nkmj.galenos.2021.816166
AMA Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. . 2021; 67 - 71. 10.4274/nkmj.galenos.2021.816166
Vancouver Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. . 2021; 67 - 71. 10.4274/nkmj.galenos.2021.816166
IEEE Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a "Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi." , ss.67 - 71, 2021. 10.4274/nkmj.galenos.2021.816166
ISNAD Uludağ, Server Sezgin vd. "Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi". (2021), 67-71. https://doi.org/10.4274/nkmj.galenos.2021.816166
APA Uludağ S, AKINCI O, ergun s, Erginöz E, SANLI A, kepil n, Ayan F, OZCELIK M, zengin a (2021). Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. Namık Kemal Tıp Dergisi, 9(1), 67 - 71. 10.4274/nkmj.galenos.2021.816166
Chicago Uludağ Server Sezgin,AKINCI OZAN,ergun sefa,Erginöz Ergin,SANLI AHMET NECATI,kepil nuray,Ayan Fadıl,OZCELIK MEHMET FAIK,zengin abdullah kağan Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. Namık Kemal Tıp Dergisi 9, no.1 (2021): 67 - 71. 10.4274/nkmj.galenos.2021.816166
MLA Uludağ Server Sezgin,AKINCI OZAN,ergun sefa,Erginöz Ergin,SANLI AHMET NECATI,kepil nuray,Ayan Fadıl,OZCELIK MEHMET FAIK,zengin abdullah kağan Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. Namık Kemal Tıp Dergisi, vol.9, no.1, 2021, ss.67 - 71. 10.4274/nkmj.galenos.2021.816166
AMA Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. Namık Kemal Tıp Dergisi. 2021; 9(1): 67 - 71. 10.4274/nkmj.galenos.2021.816166
Vancouver Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi. Namık Kemal Tıp Dergisi. 2021; 9(1): 67 - 71. 10.4274/nkmj.galenos.2021.816166
IEEE Uludağ S,AKINCI O,ergun s,Erginöz E,SANLI A,kepil n,Ayan F,OZCELIK M,zengin a "Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi." Namık Kemal Tıp Dergisi, 9, ss.67 - 71, 2021. 10.4274/nkmj.galenos.2021.816166
ISNAD Uludağ, Server Sezgin vd. "Özefagus Karsinomlarının 33 Yıllık Retrospektif Analizi: Cerrahpaşa Deneyimi". Namık Kemal Tıp Dergisi 9/1 (2021), 67-71. https://doi.org/10.4274/nkmj.galenos.2021.816166